Palisade Bio Inc (PALI)

[Lcbm68]

My friend we are all adding here in Asia at market opening ~ let’s take amc to the moon

Great and exciting days ahead and we have control total control

Lcbm68

[JJL]

I am adding.

[Lcbm68]

Hold long n strong bro

[Lcbm68]

Hold strong we are building a foundation so don’t lose hope ~ the tide is going to turn fast

[Lcbm68]

We are behind you Asian Apes buying back now and the fun is about to begin

Lock n load guys

Lcbm68

[INFINITI]

Shorts better cover

[INFINITI]

Cmon second round coming $$$

[crudeoil24]

Palisade Bio, Inc, formerly Seneca Biopharma, Inc., is a biopharmaceutical company. The Company is focused on developing therapies that helps patients with acute and chronic gastrointestinal problems from post-operative digestive enzyme damage. Its product candidate, LB1148, is a Phase III-ready protease inhibitor which is developed to reduce abdominal adhesions and help restore bowel function following surgery. It is engaged in developing oral product candidates to treat conditions driven by protease (intestinal digestive enzymes) escaping the intestines, including surgical problems and inflammatory conditions. Its LB1148 is an oral formulation of a serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery.

[INFINITI]

Let it run folks we can break $2

[INFINITI]

Slap that as$$$k

[INFINITI]

Palisade Bio wins FDA nod to run late-stage trial for lead candidate

[INFINITI]

Got some let’s gooo$$$

[crudeoil24]

Great news! LET'S GO PALI!

[makinezmoney]

$PALI: FDA Approval for proceeding to Phase 3

$PALI(.80) up .80 Company received a “Study May Proceed” letter from the U.S. Food and Drug Administration (FDA) for a Phase 3 clinical trial to evaluate LB1148 to accelerate the return of bowel function in adult patients undergoing bowel/abdominal surgery.



GO $PALI

[81vette]

twitter lies,i lost $530 on this garbage

[Inve$tor77]

What news ?

[MASTERULTRA]

Bunch of assholes selling...

[MASTERULTRA]

What the fuck is going on? What a fucking piece of shit...

[81vette]

low float,OS 13m,getting noticed,hot news

[81vette]

zero borrow/no shares to short!!! up up up

[Pyramid2]

boom

[$treet $inatra]

Ultra-thin. $1.69 premarket - lets get there today. Easy $5-$10 target here

https://stockcharts.com/c-sc/sc?s=PALI&p=W&yr=2&mn=3&dy=0&i=t7708495307c&r=1643720581545

https://s27.q4cdn.com/263494128/files/doc_downloads/Palisade-Bio-Corporate-Presentation.pdf

NASDAQ Nano Float & 13.5M O/S

https://palisadebio.com

[traderbbc1]

Not sure...One thing I do know, lousy stock performance

[BesaoT35]

This stock was $10 in May 2021. It was nonstop severely terrible stock performance since then. Down 85% in 6 months.

Whatever happened to NSI-189 which grew neurons in the hippocampus?

[pilotnick]

I posted this in Yahoo and thought it should be posted here too!

Pali is not going anywhere until Nov 1st. As I mentioned before the days after the 24th to the 29th are the days that matter to Altium. Read below this is taken from the prospectus of the 7.262 million shares. their warrants get re priced.

The Bridge Warrants and Equity Warrants provide that, until the second anniversary of the date on which all shares of Company?s common stock issued to the Investor (including any shares underlying the Equity Warrants) are registered on one or more registration statements, if the Company publicly announces, issues or sells, enters into a definitive, binding agreement pursuant to which the Company is required to issue or sell or is deemed, pursuant to the provisions of the Bridge Warrants and Equity Warrants, to have issued or sold, any shares of the Company?s common stock for a price per share lower than the exercise price then in effect, subject to certain limited exceptions, then the exercise price of the Bridge Warrants and Equity Warrants shall be reduced to such lower price per share. Further, on preset reset dates, the exercise price of the Bridge Warrants and Equity Warrants was to be adjusted downward (but not increased)(the ?Resets?). Further, the Equity Warrants include a provision such that, beginning six months after the closing of the Merger, if the volume weighted average price of Company Common Stock is less than the then-applicable exercise price for five consecutive trading days, the holder of the Equity Warrant shall be entitled to receive 1.0 share of Company Common Stock for each share underlying the Equity Warrants being exercised thereunder in a cashless exercise. The exercise price and the number of shares of Company Common Stock issuable upon exercise of the Bridge Warrants and Equity Warrants will also be subject to adjustment in the event of any stock splits, dividends or distributions or other similar transactions as well as fundamental transactions. Prior to the effectiveness of the Waiver and Amendment Agreement (described below), two Resets occurred and the two Bridge Warrants and the Equity Warrants were exercisable for up to 429,446, 429,446, and 5,303,568 shares, respectively, each at an exercise price of $3.88 per share, and two potential Resets remained.

So to explain in plain English 6 months is 180 days, the merger closed on April 27th. So six months (180 days from April 27th is October 24th. Five trading days after are the 25th thru 29th. Altium is going to keep it down until then.

When it dips you buy!!!

[XenaLives]

What's going on here?

PALI news: Palisade Bio inks worldwide in-licensing agreement with University of California
Jul. 13, 2021 8:41 AM ETPalisade Bio, Inc. (PALI)By: Aakash Babu, SA News Editor
Palisade Bio (NASDAQ:PALI) has entered into an exclusive license with the Regents of the University of California, expanding its proprietary technology for detecting enzymatic protease activity in human clinical samples.
Under the terms of the agreement, the company receives a worldwide exclusive license to patent rights covering certain engineered substrates and their use in measuring degradative enzymes for disease conditions, including cancer.

[Inve$tor77]

Nice volume and buys today. Big green candle

[traderbbc1]

Reversal day

[JackAskSlap]

Sorry I'm not the guy for those answers. I mainly just front load a good oversold chart

[myjo]

Does anyone know when they are starting Phase 3 trials?

[JackAskSlap]

Still here Sharky? I'm liking the slow steady accumulation, so far its added up to nice size pile without having to chase the dawgs around the yard

[sharky]

Churning



$PALI

[traderbbc1]

I added to my position Friday.

[sharky]

PALI at 52 week lows, with 52 week high over 10.00



$PALI

[JackAskSlap]

re grouping next week PALI should be a sweet grab

[traderbbc1]

UGLY

[sharky]

PALI weekly chart:







$PALI

[sharky]

Nice opps IMO





$PALI

[traderbbc1]

Look At CLSN. Same chart. Good news today. They are up 6%.

[traderbbc1]

hence the gap and trap.

[$treet $inatra]

Great but seems the co likes to sell into the news... nice volume and nice $4.70 premarket spike!

[traderbbc1]

A classic gap and trap on good news. This is not a short term play. It will be a rocket ship soon enough.
JMO
Not selling my SNCA/PALI

[Natural Trader]

WTF red on good news

[sharky]

Great chart setup IMO



$PALI

[traderbbc1]

Sad. Nearly flat on the day.

[traderbbc1]

Science will take us there. Not a political statement.

[sharky]

Looking forward to trading over 10.00 again here IMO



$PALI

[traderbbc1]

If it's a blockbuster...Can you say takeover.
JMO

[sharky]

PALI news: Palisade Bio and Newsoara Announce Positive Topline Efficacy Results from Phase 2 Study of LB1148 Demonstrating Accelerated Return of Bowel Function After Gastrointestinal Surgery
July 29 2021 - 08:15AM
GlobeNewswire Inc.

Share On Facebook

Palisade Bio, Inc. (Nasdaq: PALI) and co-development partner Newsoara today announced positive topline Phase 2 clinical trial data that LB1148 had a statistically significant (p=0.0008) effect in accelerating the return of bowel function in patients undergoing elective bowel resection surgery.
“These results demonstrate a strong efficacy profile in acceleration of the time to recover bowel function combined with a favorable safety and tolerability profile,” said Tom Hallam, Ph.D., CEO of Palisade Bio. “We believe LB1148 can simplify the surgical journey for these patients, helping them get better faster, while potentially reducing costs to the healthcare system. Further, LB1148 has now shown statistically significant acceleration of return of bowel function in a Phase 2 study for cardiovascular surgery and in a Phase 2 study for GI surgery. These data lay the important groundwork for proceeding to pivotal studies for these indications. We are grateful to all patients that participated in this trial as well as our international collaborators, and we look forward to continued efforts to bring this therapy to patients in need.”

“We are delighted that the results from our Phase 2 study brings us another step closer to potentially launching the first protease inhibitor indicated to accelerate the return of GI function,” said Dr Benny Li, Newsoara’s Chief Executive Officer. “Delayed return of bowel function impacts millions of patients across the globe every year, yet the treatment landscape for this global population has been relatively unchanged for decades. LB1148 has the potential to be transformative for patients undergoing major surgery to address this significant unmet need.”

The Phase 2, multicenter, randomized, double-blind, parallel, placebo-controlled clinical trial was completed as part of a co-development agreement between Palisade Bio and Newsoara. The study involved 120 patients undergoing elective bowel resection surgery and included laparotomy and laparoscopic surgical approaches. In addition, the study included patients undergoing either anastomosis or stoma creation. The primary outcome was recovery of bowel function measured as the time from the end of surgery to oral food tolerance and passage of stool.

Results from the study include:

A 1.1-day improvement in GI recovery in patients receiving LB1148 vs placebo. The median time to return of bowel function was 2.77 days in patients treated with LB1148 and 3.83 days in those receiving placebo (hazard ratio = 1.886; p = 0.0008).
The difference between groups increased at the 3rd quartile (75th percentile), with LB1148 (3.4 days) demonstrating a 1.5-day faster recovery of bowel function compared to placebo (4.9 days).
LB1148 was well tolerated with only 10.9% and 4.8% of patients in the LB1148 group and placebo group, respectively, experiencing a drug-related adverse event.
The most common drug-related adverse events were GI disorders (LB1148 4.7% vs. placebo 3.2%). No drug-related serious adverse events occurred in the trial.
Dr. Michael Dawson, M.D., Palisade Bio's Chief Medical Officer added, “It's very encouraging that the accelerated return of bowel function due to LB1148 in this study is larger in magnitude than any of the five controlled studies that were submitted to the U.S. FDA for approval of Entereg, the only approved product in this indication. Full results from this study are expected to be reported at an upcoming surgical-focused medical conference later this year.”

Based on the beneficial clinical outcomes and good safety profile observed to date in phase 2 trials in both CV surgery and GI surgery, Palisade Bio and Newsoara plan to advance LB1148 to pivotal Phase 3 clinical trials for accelerating the return of bowel function for major surgical indications.

About LB1148
LB1148 is an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. Evidence suggests that the release of digestive proteases contributes to the temporary loss of normal gastrointestinal function and formation of postoperative adhesions. By inhibiting the activity of these digestive proteases, LB1148 has the potential to prevent damage to GI tissues, accelerate the time to return of normal GI function, and shorten the duration of costly post-surgery hospital stays.

About Palisade Bio, Inc.
Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from a Phase 2 trial of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return to bowel function and decrease in length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications associated with chronic disruption of the gastrointestinal epithelial barrier. For more information, please go to www.palisadebio.com.


$PALI

[traderbbc1]

Well...Were getting closer to the finish line. It looks like we have significant positive results. I'm surprised we didn't see a double this AM.